Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10323703" target="_blank" >RIV/00064203:_____/16:10323703 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/16:10323703

Result on the web

<a href="http://dx.doi.org/10.1007/s00467-015-3225-0" target="_blank" >http://dx.doi.org/10.1007/s00467-015-3225-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00467-015-3225-0" target="_blank" >10.1007/s00467-015-3225-0</a>

Result language

angličtina

Original language name

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

Original language description

Background Limited prospective data are available on the long-term safety of darbepoetin alfa (DA) for treating anemia in children with chronic kidney disease (CKD). Methods In this prospective, phase IV, observational registry study, children <= 16 years of age with CKD anemia and receiving DA were observed for <= 2 years. Adverse events (AEs), DA dosing, hemoglobin (Hb) concentrations, and transfusions were recorded. Results A total of 319 patients were included in the analysis (mean age, 9.1 years), 158 (49.5 %) of whom were on dialysis at study entry. Of 434 serious AEs reported in 162 children, the most common were peritonitis (10.0 %), gastroenteritis (6.0 %), and hypertension (4.1 %). Six patients (1.9 %) died (unrelated to DA). Four patients (1.3 %) experienced six serious adverse drug reactions. The geometric mean DA dose range was 1.4-2.0 mu g/kg/month. Mean baseline Hb concentration was 11.1 g/dl; mean values for children receiving and not receiving dialysis at baseline ranged between 10.9 and 11.5 g/dl and 11.2-11.7 g/dl, respectively. Overall, 48 patients (15.0 %) received >= 1 transfusion. Conclusions No new safety signals for DA were identified in children receiving DA for CKD anemia for <= 2 years. Based on Hb concentrations and transfusion requirements, DA was effective at managing anemia in these patients.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FG - Paediatrics

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pediatric Nephrology

ISSN

0931-041X

e-ISSN

—

Volume of the periodical

31

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

443-453

UT code for WoS article

000371425100013

EID of the result in the Scopus database

2-s2.0-84958912673